This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Gastrointestinal

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

MOVENTIG (naloxegol)

MOVENTIG is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).1

 

  • INTRODUCTION

    MOVENTIG belongs to a class of drugs known as peripherally acting mu-opioid receptor antagonists (PAMORAs).1 PAMORAs are designed to relieve constipation without compromising the analgesic action of opioids.

  • EFFICACY

    Evidence from clinical studies demonstrating MOVENTIG's efficacy in relieving OIC in non-cancer patients.

  • EFFICACY IN PATIENTS WITH CANCER

    Evidence from clinical studies demonstrating MOVENTIG's efficacy in relieving OIC in cancer patients.

  • HOW TO PRESCRIBE

    Guidance on how to prescribe MOVENTIG.

  • TOLERABILITY

    MOVENTIG has been shown to be generally well-tolerated for up to 52 weeks.2 Read about the most commonly reported adverse drug reactions encountered here.

  • PRESCRIBING INFORMATION

    Direction on prescribing MOVENTIG covering information from dosage ranges to precautions.

RECTOGESIC (glyceryl trinitrate)

Rectogesic is the only medicine licensed in the UK for the treatment of pain associated with chronic anal fissure (CAF).3,4 With a uniform, quality assured formulation, Rectogesic has been prescribed worldwide for over 16 years.5 

  • INTRODUCTION

    Find out about Rectogesic, the only treatment licensed in the UK for pain relief of chronic anal fissure,3,4 relieving pain of over 3 million fissures worldwide since launch.6

  • EFFICACY

    Results from Phase III trials showed effective pain relief for chronic anal fissure within days, sustained over 8 week treatment period as fissure heals.7

  • TOLERABILITY

    In clinical studies over 86% of patients completed their course of treatment.8 Read about how most headaches can be managed using simple analgesics.3

  • HOW TO PRESCRIBE

    Guidance on how to prescribe Rectogesic, including dosing, storage and administration.

  • GLOSSARY

    Key terminology used in the management of chronic anal fissure.

  • PRESCRIBING INFORMATION

    Direction on prescribing Rectogesic, covering information from dosing to precautions.

Average:

  • References

    1. MOVENTIG® (naloxegol). Summary of Product Characteristics.

    2. Webster L et al. Alimentary Pharmacology & Therapeutics 2014; 40(7):771-779.

    3. Rectogesic® Summary of Product Characteristics (UK) – Revised July 2020.

    4. British National Formulary Online https://bnf.nice.org.uk/treatment-summary/anal-fissure.html - Last accessed July 2022.

    5. Kyowa Kirin Data on File - DOF-UK-074-Rectogesic.

    6. Kyowa Kirin Data on File - DOF-UK-073-Rectogesic.

    7. Bailey HR, Beck DE, Billingham RP, et al. A study to determine the nitroglycerin ointment dose and dosing interval that best promote the healing of chronic anal fissures. Dis Colon Rectum 2002: 45(9):1192-1199.

    8. Berry SM, Barish CF, Bhandari R, et al. Nitroglycerin 0.4% ointment vs placebo in the treatment of pain resulting from chronic anal fissure: a randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013 Jul 1;13:106.

    KKI/INT/KKI/0603 November 2023